STAT6 signaling has been implicated specifically in treatment resistance and progression in several malignancies, including the response of chronic lymphocytic leukemia cells to B-cell receptor-mediated treatment and radioresistance in inflammatory breast cancer cells 40, 41, 42, 43. This evidence concerns the gene STAT6 and B-cell chronic lymphocytic leukemia.